• November 2013
    Dr. Moore Joins Board of Directors of LiteFood Incorporated
    • Dr. Roscoe M. Moore Jr. has been appointed to the Board of Directors of the United States subsidiary of the publicly traded Australian company, Holista CollTech Limited. LiteFood Incorporated is its new United States subsidiary. Holista CollTech Limited researches, develops, manufactures, and markets health style products, and is based in Perth, Australia. LiteFood Incorporated, will focus on commercializing Holista CollTech Limited's core low fat, low glycemic index, low sodium salt, and low calorie sugar products. America invented processed and fast foods, and many top global brands are based in the United States. Obesity, diabetes, and cardiovascular diseases are increasingly being attributed to the prevalence of processed and fast foods. Dr. Moore has joined LiteFood Incorporated to constantly look for healthier solutions in the fast-food industry by seeking more healthy dietary intake food products, whenever possible. Dr. Moore served as United States Assistant Surgeon General until his retirement.
  • June 2013
    Dr. Moore Joins Board of Directors of OyaGen
    • Dr. Roscoe M. Moore Jr. has been appointed to the Board of Directors of OyaGen Incorporated based in Rochester, New York. OyaGen is a small biotechnology which is developing innovative novel, patent protected therapeutics for HIV/AIDS and other infectious diseases that are in pre-clinical development. OyaGen has developed a robust intellectual portfolio to support its growing pipeline of HIV/AIDS drug candidates and proprietary drug targets. In addition to its investors, OyaGen's research has received financial support from the National Institutes of Health (NIH) and the Gates Foundation, as well as a number of other public and private sources.  OyaGen's technology is based on the platform of editing enzymes. Editing enzymes function has been linked to our natural ability to fight off viral infection. OyaGen seeks to develop novel therapeutics to regulate editing enzyme activity. Patents are issued or pending on all proposed therapies. OyaGen holds the exclusive rights to these important technologies originating from the University of Rochester Medical Center and other medical research institutions. Dr. Moore served as a career officer in the Commissioned Corps of the U.S. Public Health Service, achieving the rank of Assistant U.S. Surgeon General. Dr. Moore has authored over 100 publications on a range of public health issues, including HIV/AIDS. He served on the Advisory Board of Directors of the Fogarty International Center, NIH, appointed by the U.S. Secretary of Health and Human Services. Dr. Moore is a Fellow of the American College of Epidemiology and has been involved in the HIV/AIDS epidemic since its beginning.